当前位置: X-MOL 学术Brain Behav. Immun. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder
Brain, Behavior, and Immunity ( IF 8.8 ) Pub Date : 2020-07-01 , DOI: 10.1016/j.bbi.2020.03.021
Kyu-Man Han 1 , Woo-Suk Tae 2 , Aram Kim 3 , Youbin Kang 3 , Wooyoung Kang 3 , June Kang 4 , Yong-Ku Kim 5 , Bongcheol Kim 6 , Jae Young Seong 7 , Byung-Joo Ham 8
Affiliation  

Chronic low-grade inflammation contributes to the pathophysiology of major depressive disorder (MDD). This study aimed to examine the association between serum levels of FAM19A5, a novel chemokine-like peptide that reflects reactive astrogliosis and inflammatory activation in the brain, and the neurodegenerative changes of MDD by investigating the correlation between serum FAM19A5 levels and cortical thickness changes in patients with MDD. We included 52 drug-naïve patients with MDD and 60 healthy controls (HCs). Serum FAM19A5 levels were determined in peripheral venous blood samples using a sandwich enzyme-linked immunosorbent assay. All participants underwent T1-weighted structural magnetic resonance imaging. Serum FAM19A5 levels were greater in patients with MDD than in HCs. In the MDD group, there were significant inverse correlations between serum FAM19A5 levels and cortical thickness in the prefrontal regions (i.e., the left inferior and right medial superior frontal gyri), left posterior cingulate gyrus, right cuneus, and both precunei, which showed significantly reduced thickness in patients with MDD compared to HCs. However, no correlation between serum FAM19A5 level and cortical thickness was observed in the HC group. The results of our study indicate that serum FAM19A5 levels may reflect reactive astrogliosis and related neuroinflammation in MDD. Our findings also suggest that serum FAM19A5 may be a potential biomarker for the neurodegenerative changes of MDD.

中文翻译:

血清 FAM19A5 水平:重度抑郁症神经炎症和神经退行性变的新型生物标志物

慢性低度炎症有助于重度抑郁症 (MDD) 的病理生理学。本研究旨在通过研究血清 FAM19A5 水平与患者皮质厚度变化之间的相关性,来研究 FAM19A5(一种反映大脑反应性星形胶质细胞增生和炎症激活的新型趋化因子样肽)血清水平与 MDD 神经退行性变化之间的关联。与 MDD。我们纳入了 52 名未接受药物治疗的 MDD 患者和 60 名健康对照 (HC)。使用夹心酶联免疫吸附测定法测定外周静脉血样品中的血清 FAM19A5 水平。所有参与者都接受了 T1 加权结构磁共振成像。MDD 患者的血清 FAM19A5 水平高于 HC。在 MDD 组中,血清 FAM19A5 水平与前额叶区(即左侧额下回和右侧内侧上回)、左后扣带回、右楔叶和两个前叶的皮质厚度呈显着负相关,显示出患者的皮质厚度显着降低。 MDD 与 HC 相比。然而,在HC组中未观察到血清FAM19A5水平与皮质厚度之间的相关性。我们的研究结果表明,血清 FAM19A5 水平可能反映了 MDD 中的反应性星形胶质细胞增生和相关的神经炎症。我们的研究结果还表明,血清 FAM19A5 可能是 MDD 神经退行性变化的潜在生物标志物。右楔骨和楔前叶,与 HC 相比,MDD 患者的厚度显着降低。然而,在HC组中未观察到血清FAM19A5水平与皮质厚度之间的相关性。我们的研究结果表明,血清 FAM19A5 水平可能反映了 MDD 中的反应性星形胶质细胞增生和相关的神经炎症。我们的研究结果还表明,血清 FAM19A5 可能是 MDD 神经退行性变化的潜在生物标志物。右楔骨和楔前叶,与 HC 相比,MDD 患者的厚度显着降低。然而,在HC组中未观察到血清FAM19A5水平与皮质厚度之间的相关性。我们的研究结果表明,血清 FAM19A5 水平可能反映了 MDD 中的反应性星形胶质细胞增生和相关的神经炎症。我们的研究结果还表明,血清 FAM19A5 可能是 MDD 神经退行性变化的潜在生物标志物。
更新日期:2020-07-01
down
wechat
bug